How many 8-K filings has Zevra Therapeutics, Inc. filed?

Zevra Therapeutics, Inc. (ZVRA) has 28 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Zevra Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Zevra Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Zevra Therapeutics, Inc. (ZVRA) — 8-K Filings

All 8-K filings from Zevra Therapeutics, Inc.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

Zevra Therapeutics Announces Board and Executive Changes — Dec 17, 2025 Risk: medium
On December 11, 2025, Zevra Therapeutics, Inc. announced changes in its board of directors and executive compensation arrangements. The filing details the depar
8-K Filing — Dec 2, 2025
Zevra Therapeutics Files 8-K on Governance and Compensation — Nov 20, 2025 Risk: low
On November 20, 2025, Zevra Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
Zevra Therapeutics Files 8-K on Security Holder Vote — May 29, 2025 Risk: low
On May 29, 2025, Zevra Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify t
Zevra Therapeutics Files 8-K on Asset Disposition & Financials — Apr 7, 2025 Risk: medium
On April 1, 2025, Zevra Therapeutics, Inc. reported on the completion of an acquisition or disposition of assets, as well as its results of operations and finan
Zevra Therapeutics Files 8-K on Financials — Mar 11, 2025 Risk: low
Zevra Therapeutics, Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
Zevra Therapeutics Files 8-K with Material Agreement — Feb 27, 2025 Risk: medium
On February 26, 2025, Zevra Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financia
Zevra Therapeutics Appoints New Officers, Reports Q3 Loss — Dec 6, 2024 Risk: medium
On December 2, 2024, Zevra Therapeutics, Inc. announced the appointment of Dr. Michael L. Smith as Chief Medical Officer and Dr. David M. Reif as Chief Scientif
Zevra Therapeutics Files 8-K: Reg FD, Other Events — Nov 22, 2024 Risk: low
On November 21, 2024, Zevra Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial sta
Zevra Therapeutics Files 8-K on Financials — Nov 12, 2024 Risk: low
On November 12, 2024, Zevra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
Zevra Therapeutics Files 8-K Report — Sep 20, 2024 Risk: low
On September 20, 2024, Zevra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events an
Zevra Therapeutics Files 8-K on Financials — Aug 13, 2024 Risk: low
On August 13, 2024, Zevra Therapeutics, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial stat
Zevra Therapeutics Files 8-K Report — Aug 9, 2024 Risk: low
On August 8, 2024, Zevra Therapeutics, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as KemPharm, Inc.,
Zevra Therapeutics Files 8-K on Financials — Aug 8, 2024 Risk: low
Zevra Therapeutics, Inc. filed an 8-K on August 8, 2024, to report on its results of operations and financial condition. The filing does not contain specific fi
Zevra Therapeutics Files 8-K — Aug 5, 2024 Risk: low
On August 2, 2024, Zevra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, along with other
Zevra Therapeutics Terminates Material Agreement — Jul 12, 2024 Risk: medium
On July 12, 2024, Zevra Therapeutics, Inc. filed an 8-K report detailing the termination of a material definitive agreement. The filing also includes financial
Zevra Therapeutics Files 8-K Report — Jul 9, 2024 Risk: low
On July 9, 2024, Zevra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
Zevra Therapeutics Files 8-K Report — Jun 3, 2024 Risk: low
On June 3, 2024, Zevra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
Zevra Therapeutics Holds Annual Stockholder Meeting — May 13, 2024 Risk: low
On May 13, 2024, Zevra Therapeutics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders voted on
Zevra Therapeutics Files 8-K on Financials — May 8, 2024 Risk: low
Zevra Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
Zevra Therapeutics Enters New Agreement, Terminates Old One — Apr 10, 2024 Risk: medium
On April 4, 2024, Zevra Therapeutics, Inc. entered into a Material Definitive Agreement and simultaneously terminated a prior Material Definitive Agreement. The
Zevra Therapeutics Restates Financials Due to Internal Control Weakness — Mar 28, 2024 Risk: medium
Zevra Therapeutics, Inc. announced on March 28, 2024, that its previously issued financial statements for the fiscal year ended December 31, 2023, and the inter
Zevra Therapeutics Files 8-K Report — Mar 27, 2024 Risk: low
On March 26, 2024, Zevra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, indicating u
Zevra Therapeutics Files 8-K — Mar 5, 2024 Risk: low
Zevra Therapeutics, Inc. filed an 8-K on March 5, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
Zevra Therapeutics, Inc. Files 8-K — Mar 4, 2024 Risk: low
Zevra Therapeutics, Inc. filed an 8-K on March 4, 2024, reporting a name change from KemPharm, Inc. to Zevra Therapeutics, Inc. effective May 30, 2013. The comp
Zevra Therapeutics Amends Bylaws, Changes Fiscal Year — Feb 28, 2024 Risk: low
Zevra Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting an event that occurred on February 22, 2024. The filing indicates amendments to its Articl
Zevra Therapeutics Updates Executive Compensation Arrangements — Jan 23, 2024
Zevra Therapeutics, Inc. filed an 8-K on January 23, 2024, to report changes in its executive compensation arrangements. This filing, under Item 5.02, indicates
Zevra Therapeutics Confirms Nasdaq Listing for ZVRA Common Stock — Jan 8, 2024
Zevra Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its Common Stock is registered on The Nasdaq Stock Market under the trading

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX